Lantheus Holdings to Host First Quarter 2022 Earnings Conference Call and Webcast on April 29, 2022 at 8:00 a.m. Eastern Time

Rhea-AI Summary

Lantheus Holdings (NASDAQ: LNTH) will host a conference call on April 29, 2022, at 8:00 a.m. ET to discuss its Q1 2022 financial and operating results. Investors can access the call via telephone or through a live webcast on the company's investor website. A replay will be available two hours post-call for 30 days. Lantheus, based in North Billerica, Massachusetts, specializes in imaging diagnostics and therapeutics, with a diverse product portfolio including DEFINITY®, PYLARIFY®, and RELISTOR®.

Positive

• The upcoming conference call indicates transparency and engagement with investors.
• Lantheus maintains a diverse product portfolio in imaging diagnostics and therapeutics.

Negative

• None.

NORTH BILLERICA, Mass., April 15, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Friday, April 29, 2022, to discuss its financial and operating results for the first quarter of 2022.

To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 8691334. A live webcast will also be available in the Investors section of the Company’s website at www.lantheus.com.

A replay of the webcast will be available in the Investors section of the Company’s website approximately two hours after completion of the call and will be archived for 30 days.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow^® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY^® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY^®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI^™, an artificial intelligence platform that assists in the evaluation of PSMA PET images; TechneLite^® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA^® for the treatment of certain rare neuroendocrine tumors; and RELISTOR^® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts, with additional offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.

Contacts:

Mark Kinarney
Senior Director, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Senior Director, Corporate Communications
646-975-2533
media@lantheus.com

FAQ

What date is Lantheus hosting its Q1 2022 financial results call?

Lantheus is hosting its Q1 2022 financial results call on April 29, 2022.

How can I access Lantheus' conference call?

You can access Lantheus' conference call via telephone or through a live webcast on their investor website.

What products does Lantheus offer?

Lantheus offers products like DEFINITY®, PYLARIFY®, and RELISTOR® among others.

What time is the Lantheus conference call scheduled?

The Lantheus conference call is scheduled for 8:00 a.m. ET.

Is there a replay available for the Lantheus conference call?

Yes, a replay of the conference call will be available approximately two hours after completion for 30 days.